NeuroOne Medical Technologies Files 2024 10-K

Ticker: NMTC · Form: 10-K · Filed: Dec 17, 2024 · CIK: 1500198

Neuroone Medical Technologies CORP 10-K Filing Summary
FieldDetail
CompanyNeuroone Medical Technologies CORP (NMTC)
Form Type10-K
Filed DateDec 17, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $15.5 billion, $10,000, $15,000, $2.5
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, medical-devices

TL;DR

NeuroOne Medical Technologies filed its 2024 10-K. Full financial picture inside.

AI Summary

NeuroOne Medical Technologies Corporation filed its annual report for the fiscal year ended September 30, 2024. The company, incorporated in Delaware and headquartered in Eden Prairie, MN, operates in the surgical and medical instruments sector. The filing covers their performance and financial status for the period.

Why It Matters

This 10-K filing provides investors and stakeholders with a comprehensive overview of NeuroOne Medical Technologies' financial health, operational performance, and strategic direction for the fiscal year 2024.

Risk Assessment

Risk Level: medium — As a medical technology company, NeuroOne faces risks related to product development, regulatory approvals, market adoption, and competition, which are typical for this industry.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of NeuroOne Medical Technologies Corporation?

NeuroOne Medical Technologies Corporation is involved in the Surgical & Medical Instruments & Apparatus industry, as indicated by its SIC code [3841].

For which fiscal year is this 10-K report filed?

This 10-K report is for the fiscal year ended September 30, 2024.

Where are NeuroOne Medical Technologies Corporation's principal executive offices located?

The principal executive offices are located at 7599 Anagram Dr., Eden Prairie, MN 55344.

What is the Commission File Number for NeuroOne Medical Technologies Corporation?

The Commission File Number is 001-40439.

When was this 10-K filing submitted to the SEC?

This 10-K filing was submitted on December 17, 2024.

Filing Stats: 4,396 words · 18 min read · ~15 pages · Grade level 15.6 · Accepted 2024-12-17 08:29:19

Key Financial Figures

Filing Documents

BUSINESS

BUSINESS 1 ITEM 1A.

RISK FACTORS

RISK FACTORS 27 ITEM 1B. UNRESOLVED STAFF COMMENTS 57 ITEM 1C. CYBERSECURITY 57 ITEM 2.

PROPERTIES

PROPERTIES 57 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 57 ITEM 4. MINE SAFETY DISCLOSURES 57 PART II 58 ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 58 ITEM 6. [RESERVED] 58 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 59 ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 70 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA F-1 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 71 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 71 ITEM 9B. OTHER INFORMATION 72 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 72 PART III 73 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 73 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 73 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 73 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 73 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 73 PART IV 74 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 74 ITEM 16. FORM 10-K SUMMARY 77

SIGNATURES

SIGNATURES 78 i NeuroOne Medical Technologies Corporation FORM 10-K SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Unless the context requires otherwise, references in this Annual Report on Form 10-K (this "Annual Report" or "Report") to "we," "us," "the Company" and "our" refer to NeuroOne Medical Technologies Corporation (the "Company"). This Annual Report contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the sections entitled "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business," but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include our ability to maintain regulatory clearance of our products and technology; our ability to successfully commercialize our technology in the United States; our ability to achieve or sustain profitability; our ability to raise additional cap

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing